Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).

By Audrey Chia, W. Chua, Y. Cheung, W. Wong, A. Lingham, A. Fong, Donald T. Tan. Ophthalmology (Rochester, Minn.), 2012

797 citations recorded by the source corpus.

Subfields: Epidemiology, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/039c2785bc16882c8a57dba5edd4bf0c6813ae2f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Audrey Chia
2. Donald T. Tan
3. Qingshu Lu

In Radiology, Nuclear Medicine and Imaging

1. Audrey Chia
2. Donald T. Tan
3. Qingshu Lu

Citations in the corpus

• Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. (2019, neutral): “5%, its AL elongation was still significant.(16) Of note, the efficacy of the 0.”
• Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. (2016, methodology): “4 near vision loss.(19,20) In phase 2, we further established that children receiving lower doses had less myopic progression after atropine was stopped,(20) resulting in 0.”